3413 results for «2025»
3413 results
Optimal SCAD treatment
22 May 2025 – From EuroPCR 2025
Navigate the complexities of spontaneous coronary artery dissection (SCAD) treatment through clinical case discussions. This session explores identifying the culprit lesion, recurrent ACS challenges, the conservative versus PCI treatment dilemma, and real-world presentation scenarios emphasizing decision-making in SCAD management.
The PCR-EAPCI Textbook is pleased to announce a new Editor-in-Chief!
22 May 2025
A formal handover took place on Wednesday, 21 May, in Paris during EuroPCR 2025, marking the transition from Stephan Windecker, former Editor-in-Chief, to Robert Byrne, who now assumes the role as the newly appointed Editor-in-Chief of this leading educational resource for interventional cardiologists.
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
Season’s greetings and best wishes for a bright new year
17 Dec 2024
Listen to PCR Chairman William Wijns and Co-Chairmen Jean Fajadet and Bernard Prendergast wish the community a well-deserved relaxing and rejuvenating festive season. They look forward to enjoying your company, friendship and good humour at PCR Courses all around the globe in 2025.
What to expect at PCR Tokyo Valves?
Latest learnings on the treatment of asymptomatic severe aortic stenosis from the EARLY TAVR
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.
In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage...
First guidelines for the treatment of LM disease issued by SOLACI and SIAC
22 May 2025 – From EuroPCR 2025
During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.
Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...
One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases
20 May 2025 – From EuroPCR 2025
In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.
They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to...
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...
Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).
The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...
Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Nilesh Pareek and Thomas Keeble discuss the clinical value and future potential of NIRS IVUS, a dual-modality imaging system developed by Nipro that combines intravascular ultrasound with near-infrared spectroscopy.
The Makoto™ system and Dualpro™ catheter allow real-time identification of lipid-rich plaques by providing both...
Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?
22 May 2025 – From EuroPCR 2025
How can physiology guide treatment decisions beyond ischemia detection? In this round-table recorded at EuroPCR 2025, Thomas Engstrøm, Carlos Collet and Jeroen Sonck examine how pullback pressure gradient (PPG) makes it possible to identify the distribution pattern of coronary artery disease—focal or diffuse—based on a continuous...
Duration of DAPT in ACS: The DUAL-ACS Trial
31 Aug 2025
Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.
The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...
Author
Author
1-year SELUTION DeNovo results: drug-eluting balloon strategy vs. systematic drug-eluting stent in de novo coronary disease
29 Oct 2025
Guillaume Bonnet interviews Christian Spaulding about the SELUTION DeNovo Trial he presented at TCT 2025, in San Francisco.
Prof. Christian Spaulding, principal investigator of the study, discusses the trial design, key outcomes, breaks down the nuances behind the sirolimus DCB strategy versus contemporary DES, and shares insights...
Author
Author
Introducing our recognised EuroPCR Networkers!
PCR: Collaborative, inclusive and global
15 Nov 2025 – From PCR London Valves 2025
At PCR, collaboration and inclusion are at the heart of everything we do.
Together, we create an environment where expertise is shared, talents complement each other, and diversity becomes a strength. It is this collective spirit that drives interventional cardiology forward and inspires innovation every day.
During PCR London...
Redo TAVI: how to treat different TAVI platforms when they fail?
22 May 2025 – From EuroPCR 2025
In this discussion, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.
Together, they address the main challenges faced in repeat procedures - chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies...
TRIGISTRY: Advancing real-world understanding of tricuspid valve disease
07 Nov 2025
Edoardo Zancanaro interviews Julien Dreyfus and David Messika-Zeitoun about TRIGISTRY, an international registry that builds on the TRI-SCORE — now part of the 2025 ESC guidelines. The study confirms that early referral and optimal reduction of tricuspid regurgitation are key to improving outcomes. The team now...
1-year SELUTION DeNovo results: what they mean for daily practice
29 Oct 2025
The SELUTION DeNovo trial, presented by Christian Spaulding at TCT 2025, delivers the first head-to-head comparison between a sirolimus DCB strategy and contemporary DES in PCI.
In this review, Salvatore Brugaletta breaks down the 1-year results and what these findings truly mean for everyday lesion-by-lesion decision-making.
Author
Author
Author
